Literature DB >> 34053098

The COVID-19 pandemic and associated worsening of diabetic ketoacidosis presentation in youth.

Sonia Gera1,2,3, Rachel L Longendyke1,2,3, Nori M Minich1,2,3, Sindhoosha Malay1,2,3, Jamie R Wood1,2,3.   

Abstract

Entities:  

Mesh:

Year:  2021        PMID: 34053098      PMCID: PMC8236905          DOI: 10.1111/dme.14610

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.213


× No keyword cloud information.

CONFLICT OF INTEREST

The authors have no conflicts of interest to disclose. The coronavirus 2019 (COVID‐19) pandemic has had a substantial impact on healthcare systems across the world. Initiatives such as social distancing and limitations of non‐essential services, including conversion of in‐person well‐child visits to telehealth visits, were put in place to reduce the transmission of the virus. , These limitations may have also had unforeseen consequences, especially in regard to delay of medical care in children. There is particular concern about youth with diabetic ketoacidosis (DKA) as their clinical manifestation may be subtle despite severe metabolic abnormalities. , At clinical onset, the finding of DKA has become more common worldwide, including the United States, with several implications including impaired brain growth and lower cognitive scores with only a single episode of DKA. , Thus, the objective of this study was to compare the proportion of youth with diabetes admitted to the hospital with DKA during the COVID‐19 pandemic to the previous year. This single‐centre retrospective study included youth between 9 months and 21 years of age, admitted to our hospital with diagnoses of diabetes mellitus or DKA during two defined time periods. The two time periods were 1 March to 30 June 2019 (‘Pre‐COVID‐19’) and 1 March to 30 June 2020 (‘COVID‐19’), mirroring the first wave of COVID‐19 infections in Ohio. The primary outcome of this study was prevalence of DKA, stratified by severity. Based on venous blood gas findings, mild DKA was defined as pH of 7.2–7.29 or bicarbonate (HCO3) of 10–14 mEq/L, moderate DKA was defined as pH of 7.1–7.19 or HCO3 of 5–9 mEq/L, and severe DKA was defined as pH less than 7.1 or HCO3 less than 5 mEq/L. Chi‐square and Fisher's exact tests were utilized to examine the relationship between categorical measures. Logistic regression was used to compute odds ratios for presenting in DKA. Ordinal logistic regression was used for DKA severity and Mann–Whitney U tests were used for continuous measures. Our study identified a total of 128 youth who met inclusion criteria, 64 patients were admitted during the pre‐COVID‐19 time period and 64 patients were admitted during the COVID‐19 time period. Youth presenting more than once per time period or in both time periods were only counted for their first visit. There was a higher prevalence of DKA on presentation during the COVID‐19 time period compared to the pre‐COVID‐19 time period (73% vs 47%). There was a significant worsening of DKA severity in the COVID‐19 time period compared to the pre‐COVID‐19 time period. There was no statistically significant difference in the proportion of youth with new onset diabetes presenting in DKA between the two time periods (64% vs 42%). Of the youth with new onset diabetes who presented in DKA, there was no difference in severity of DKA. There was a significantly higher proportion of youth with established diabetes who presented in DKA during the COVID‐19 time period when compared to the pre‐COVID‐19 time period (84% vs 52%). Additionally, there was a higher odds ratio for presenting in more severe DKA in the established diabetes group (OR 5.60, 95% CI [1.59–19.75]) (Table 1).
TABLE 1

Comparison of Prevalence and Severity of DKA on Presentation in Youth presenting in DKA

Pre‐COVID−19

(March–June 2019)

COVID−19

(March–June 2020)

Odds Ratio

[95% CI]

p value
Total Participants in DKA
Prevalence of DKA30/64 (47%)47/64 (73%)3.13 [1.49–6.57]0.003*
DKA Severity
Mild15/30 (50%)10/47 (21%)3.18 [1.32–7.66] 0.01*
Moderate8/30 (27%)16/47 (34%)
Severe7/30 (23%)21/47 (45%)
New Onset Diabetes Mellitus
Prevalence of DKA13/31 (42%)21/33 (64%)2.42 [0.89–6.63]0.09*
DKA Severity
Mild6/13 (46%)6/21 (29%)1.93 [0.52–7.16] 0.33*
Moderate2/13 (15%)4/21 (19%)
Severe5/13 (39%)11/21 (52%)
Established Diabetes Mellitus
Prevalence of DKA17/33 (52%)26/31 (84%)4.89 [1.51–15.86]0.008*
DKA Severity
Mild9/17 (53%)4/26 (15%)5.60 [1.59–19.75] 0.007*
Moderate6/17 (35%)12/26 (46%)
Severe2/17 (12%)10/26 (38%)

p values obtained by Wald Chi‐Square test.

Odds ratio derived from ordinal regression.

Comparison of Prevalence and Severity of DKA on Presentation in Youth presenting in DKA Pre‐COVID−19 (March–June 2019) COVID−19 (March–June 2020) Odds Ratio [95% CI] p values obtained by Wald Chi‐Square test. Odds ratio derived from ordinal regression. This study adds significant information to the growing foundation of evidence provided by previous studies from other nations on youth with primarily type 1 diabetes. , , Given the unique excess mortality and economic burden of the COVID‐19 pandemic in the United States, understanding the impact of this pandemic on the paediatric population is vital. Furthermore, this study incorporates all youth with diabetes, including type 1 and type 2, as well as the established and newly diagnosed paediatric population. Incorporating all youth with diabetes may better assist in our understanding of this vulnerable population and aid in directing resources and education. This retrospective study demonstrated a significantly higher rate and severity of DKA in patients admitted during the COVID‐19 time period. Patients with established diabetes were significantly more likely to be admitted in DKA with worsened severity during COVID‐19; this did not reach statistical significance in the new‐onset group. Although the odds ratio confidence intervals of the new‐onset group and established group overlapped, the higher overall rate and severity of DKA may have been driven by youth with previously established diagnosis of diabetes. These patients had uninterrupted access to their diabetes team via clinic visits, telehealth visits, and 24‐h phone support during COVID‐19. Parents of children with established diabetes may have chosen to not take advantage of these resources and attempted management at home to avoid undue risk of exposure at a clinic, urgent care, or ED. Alternatively, families of youth with new‐onset diabetes, who would have never experienced similar symptoms in the past, may have resorted to hospital presentation. Limitations of our study are similar to those of most single‐centre retrospective studies. Our study was limited to a small sample size in a single region in the United States which may not be representative of other regions. Despite these limitations, this study represents a comprehensive first look into the impact of COVID‐19 restrictions on complications of diabetes in the paediatric population in a large US paediatric hospital. Further large‐scale study of the paediatric diabetes population in the United States is required to confirm the effects noted in this study. With further study, we can improve the future planning and resource allocation for this vulnerable population as this pandemic continues and in the planning for future possible pandemics.
  11 in total

1.  ISPAD Clinical Practice Consensus Guidelines 2018: Diabetic ketoacidosis and the hyperglycemic hyperosmolar state.

Authors:  Joseph I Wolfsdorf; Nicole Glaser; Michael Agus; Maria Fritsch; Ragnar Hanas; Arleta Rewers; Mark A Sperling; Ethel Codner
Journal:  Pediatr Diabetes       Date:  2018-10       Impact factor: 4.866

2.  Preventing the Spread of SARS-CoV-2 With Masks and Other "Low-tech" Interventions.

Authors:  Andrea M Lerner; Gregory K Folkers; Anthony S Fauci
Journal:  JAMA       Date:  2020-11-17       Impact factor: 56.272

3.  Ketoacidosis in Children and Adolescents With Newly Diagnosed Type 1 Diabetes During the COVID-19 Pandemic in Germany.

Authors:  Clemens Kamrath; Kirsten Mönkemöller; Torben Biester; Tilman R Rohrer; Katharina Warncke; Johanna Hammersen; Reinhard W Holl
Journal:  JAMA       Date:  2020-08-25       Impact factor: 56.272

4.  New-Onset Type 1 Diabetes in Children During COVID-19: Multicenter Regional Findings in the U.K.

Authors:  Rebecca Unsworth; Susan Wallace; Nick S Oliver; Shunmay Yeung; Archana Kshirsagar; Harshini Naidu; Ruth Min Wai Kwong; Priya Kumar; Karen M Logan
Journal:  Diabetes Care       Date:  2020-08-17       Impact factor: 19.112

5.  Has COVID-19 Delayed the Diagnosis and Worsened the Presentation of Type 1 Diabetes in Children?

Authors:  Ivana Rabbone; Riccardo Schiaffini; Valentino Cherubini; Claudio Maffeis; Andrea Scaramuzza
Journal:  Diabetes Care       Date:  2020-08-10       Impact factor: 19.112

6.  The COVID-19 pandemic and associated worsening of diabetic ketoacidosis presentation in youth.

Authors:  Sonia Gera; Rachel L Longendyke; Nori M Minich; Sindhoosha Malay; Jamie R Wood
Journal:  Diabet Med       Date:  2021-06-13       Impact factor: 4.213

7.  Unintended Consequences of Coronavirus Disease-2019: Remember General Pediatrics.

Authors:  Valentino Cherubini; Anisha Gohil; Ananta Addala; Angela Zanfardino; Dario Iafusco; Tamara Hannon; David M Maahs
Journal:  J Pediatr       Date:  2020-05-08       Impact factor: 4.406

8.  Impact of Early Diabetic Ketoacidosis on the Developing Brain.

Authors:  Tandy Aye; Paul K Mazaika; Nelly Mauras; Matthew J Marzelli; Hanyang Shen; Tamara Hershey; Allison Cato; Stuart A Weinzimer; Neil H White; Eva Tsalikian; Booil Jo; Allan L Reiss
Journal:  Diabetes Care       Date:  2018-12-20       Impact factor: 19.112

9.  Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study.

Authors:  Bertrand Cariou; Samy Hadjadj; Matthieu Wargny; Matthieu Pichelin; Abdallah Al-Salameh; Ingrid Allix; Coralie Amadou; Gwénaëlle Arnault; Florence Baudoux; Bernard Bauduceau; Sophie Borot; Muriel Bourgeon-Ghittori; Olivier Bourron; David Boutoille; France Cazenave-Roblot; Claude Chaumeil; Emmanuel Cosson; Sandrine Coudol; Patrice Darmon; Emmanuel Disse; Amélie Ducet-Boiffard; Bénédicte Gaborit; Michael Joubert; Véronique Kerlan; Bruno Laviolle; Lucien Marchand; Laurent Meyer; Louis Potier; Gaëtan Prevost; Jean-Pierre Riveline; René Robert; Pierre-Jean Saulnier; Ariane Sultan; Jean-François Thébaut; Charles Thivolet; Blandine Tramunt; Camille Vatier; Ronan Roussel; Jean-François Gautier; Pierre Gourdy
Journal:  Diabetologia       Date:  2020-05-29       Impact factor: 10.122

10.  Delayed access or provision of care in Italy resulting from fear of COVID-19.

Authors:  Marzia Lazzerini; Egidio Barbi; Andrea Apicella; Federico Marchetti; Fabio Cardinale; Gianluca Trobia
Journal:  Lancet Child Adolesc Health       Date:  2020-04-09
View more
  2 in total

Review 1.  Global burden of the COVID-19 associated patient-related delay in emergency healthcare: a panel of systematic review and meta-analyses.

Authors:  Vahid Mogharab; Mahshid Ostovar; Jakub Ruszkowski; Syed Zohaib Maroof Hussain; Rajeev Shrestha; Uzair Yaqoob; Poorya Aryanpoor; Amir Mohammad Nikkhoo; Parasta Heidari; Athar Rasekh Jahromi; Esmaeil Rayatdoost; Anwar Ali; Farshid Javdani; Roohie Farzaneh; Aref Ghanaatpisheh; Seyed Reza Habibzadeh; Mahdi Foroughian; Sayyed Reza Ahmadi; Reza Akhavan; Bita Abbasi; Behzad Shahi; Arman Hakemi; Ehsan Bolvardi; Farhad Bagherian; Mahsa Motamed; Sina Taherzadeh Boroujeni; Sheida Jamalnia; Amir Mangouri; Maryam Paydar; Neda Mehrasa; Dorna Shirali; Francesco Sanmarchi; Ayesha Saeed; Narges Azari Jafari; Ali Babou; Navid Kalani; Naser Hatami
Journal:  Global Health       Date:  2022-06-08       Impact factor: 10.401

2.  The COVID-19 pandemic and associated worsening of diabetic ketoacidosis presentation in youth.

Authors:  Sonia Gera; Rachel L Longendyke; Nori M Minich; Sindhoosha Malay; Jamie R Wood
Journal:  Diabet Med       Date:  2021-06-13       Impact factor: 4.213

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.